LianBio
Industry
- Pharmaceuticals
- Specialty Pharmaceuticals
- Biotechnology
Latest on LianBio
Amid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of
The pace of new financings seems to be picking up in 2024 after a decline in the fourth quarter of 2023 relative to the last quarter of 2022, but some drug developers still are struggling to raise new
While hundreds of millions around the world were celebrating the Lunar New Year of the wood dragon, a quiet shift and new reality was settling in in the Chinese biotech sector. The country's largest c
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Novartis To Pay Argo $185m Up Fron